FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesRequirements of a QP
Topic: Pharma Industry
Video
Members
GCSG sponsored study on INVESTIGATIVE SITE Receptivity to Direct-to-Patient Shipment in Clinical Trials
Topic: Direct-to-Patient
White Paper
Members
2019 European Knowledge Forum: Presentation and Workshop Slides
Topics: Communication, Conference, Personal Development, Pharma Industry
Presentation
Members
